We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AFYA's Medical Seats Increase to 220 at UNIMA Alagoas in Brazil
Read MoreHide Full Article
Afya Limited (AFYA - Free Report) announced it has reached a total of 220 medical seats at Centro Universitário de Maceió (UNIMA Alagoas) after the recent authorization made by the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education.
The authorization leads to an increase of 80 medical seats at UNIMA Alagoas, which is housed in the city of Maceió, located in Alagoas, Brazil. The increased medical seats will come with an additional payment of R$ 1.25 million per increased seat approval, updated by IPCA from Jan 2, 2023, until the payment date.
Furthermore, the increased number of seats will contribute to the 3,583 approved seats of AFYA, thus strengthening its position to provide quality medical education in the country.
Price Performance
Shares of this medical education group and medical practice solutions provider in Brazil gained 5.6% in the past three months, outperforming the Zacks Schools industry’s 3.1% growth. The company’s focus on accretive buyouts, operational restructuring efforts and other business initiatives to offer top-tier medical education services are likely to continue boosting its growth in the upcoming period.
Image Source: Zacks Investment Research
Considering the estimate revision trend, the Zacks Consensus Estimate for 2024 earnings per share (EPS) of AFYA has been revised upward to $1.63 from $1.60 in the past 30 days. The estimated figure indicates 27.3% year-over-year growth. Also, the estimate for second-quarter EPS has moved north in the past 60 days, indicating 27.6% growth from the year-ago quarter’s reported figure.
The growth trend is solidified by a VGM Score of A, backed by a Value Score and Growth Score of A. Such an uptrend depicts analysts’ optimism about the stock’s potential.
AGS has a trailing four-quarter earnings surprise of 33.3%, on average. The stock has surged 76% in the past year. The Zacks Consensus Estimate for AGS’ 2024 sales and EPS implies growth of 7.7% and 5,200%, respectively, from the year-ago levels.
La-Z-Boy Incorporated (LZB - Free Report) currently sports a Zacks Rank of 1. LZB has a trailing four-quarter earnings surprise of 15.3%, on average. The stock has gained 38.7% in the past year.
The Zacks Consensus Estimate for LZB’s fiscal 2025 sales and EPS implies growth of 2.1% and 5%, respectively, from the year-ago levels.
SharkNinja, Inc. (SN - Free Report) currently carries a Zacks Rank of 2. SN has a trailing four-quarter earnings surprise of 12.2%, on average. The stock has risen 74.5% in the past year.
The consensus estimate for SN’s 2024 sales and EPS indicates an increase of 11.8% and 18.6%, respectively, from the year-ago levels.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AFYA's Medical Seats Increase to 220 at UNIMA Alagoas in Brazil
Afya Limited (AFYA - Free Report) announced it has reached a total of 220 medical seats at Centro Universitário de Maceió (UNIMA Alagoas) after the recent authorization made by the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education.
The authorization leads to an increase of 80 medical seats at UNIMA Alagoas, which is housed in the city of Maceió, located in Alagoas, Brazil. The increased medical seats will come with an additional payment of R$ 1.25 million per increased seat approval, updated by IPCA from Jan 2, 2023, until the payment date.
Furthermore, the increased number of seats will contribute to the 3,583 approved seats of AFYA, thus strengthening its position to provide quality medical education in the country.
Price Performance
Shares of this medical education group and medical practice solutions provider in Brazil gained 5.6% in the past three months, outperforming the Zacks Schools industry’s 3.1% growth. The company’s focus on accretive buyouts, operational restructuring efforts and other business initiatives to offer top-tier medical education services are likely to continue boosting its growth in the upcoming period.
Image Source: Zacks Investment Research
Considering the estimate revision trend, the Zacks Consensus Estimate for 2024 earnings per share (EPS) of AFYA has been revised upward to $1.63 from $1.60 in the past 30 days. The estimated figure indicates 27.3% year-over-year growth. Also, the estimate for second-quarter EPS has moved north in the past 60 days, indicating 27.6% growth from the year-ago quarter’s reported figure.
The growth trend is solidified by a VGM Score of A, backed by a Value Score and Growth Score of A. Such an uptrend depicts analysts’ optimism about the stock’s potential.
Zacks Rank & Other Key Picks
Afya currently carries a Zacks Rank #2 (Buy).
Here are other top-ranked stocks from the Consumer Discretionary sector.
PlayAGS, Inc. (AGS - Free Report) presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks Rank #1 stocks here.
AGS has a trailing four-quarter earnings surprise of 33.3%, on average. The stock has surged 76% in the past year. The Zacks Consensus Estimate for AGS’ 2024 sales and EPS implies growth of 7.7% and 5,200%, respectively, from the year-ago levels.
La-Z-Boy Incorporated (LZB - Free Report) currently sports a Zacks Rank of 1. LZB has a trailing four-quarter earnings surprise of 15.3%, on average. The stock has gained 38.7% in the past year.
The Zacks Consensus Estimate for LZB’s fiscal 2025 sales and EPS implies growth of 2.1% and 5%, respectively, from the year-ago levels.
SharkNinja, Inc. (SN - Free Report) currently carries a Zacks Rank of 2. SN has a trailing four-quarter earnings surprise of 12.2%, on average. The stock has risen 74.5% in the past year.
The consensus estimate for SN’s 2024 sales and EPS indicates an increase of 11.8% and 18.6%, respectively, from the year-ago levels.